ArticleAmerican journal of cancer research2019
p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.
Pei-Ming Yang et al.PubMed ↗Full text ↗
No numbers read from the abstract.
22 papers cite it
this papercites it